Thursday December 3, 2015 0 comments
WESTMINSTER -- Surefire Medical Inc., a commercial-stage company developing a new class of direct-to-tumor delivery systems used in minimally invasive interventional procedures, announced the completion of a $15 million Series C financing round.
The round was led by Tullis Health Investors. Proceeds will be used for a global launch of the company’s Surefire Precision device specifically designed to meet the critical need for targeted delivery systems in the treatment of primary liver cancer.
“Tullis Health Investors looks forward to working with Surefire Medical on domestic and international commercial expansion, in particular the opportunity for Surefire in China,” said John Tullis, partner at Tullis Health Investors.
“With more than 50 percent of global primary liver cancer cases occurring in China, the launch of the Precision is positioning Surefire to drive adoption by physicians performing embolization procedures and may also help decrease overall treatment costs.”
KMG Capital Partners, Partisan Management Group, MCG Partners, High Country Ventures and angel investors also took part in the latest financing.
“With the closing of this Series C financing and our collaboration with the Tullis team, we are launching our innovative and new Precision technology to physicians worldwide for treatment of primary liver cancers,” said James Chomas, Surefire Medical president and CEO.
“The growing body of clinical evidence suggests that increasing the amount of therapeutic agents delivered into the tumor may improve patient response and overall survival. With the Surefire technology, more of the dose reaches the tumor while sparing healthy tissue.”